{
  "pmcid": "9750631",
  "sha256": "779d4eb12bc0c34410a54ee7fe1bf2aa70800d497322fcd309948f37605f35d4",
  "timestamp_utc": "2025-11-09T23:02:00.963640+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.311645320197048,
    "reading_ease": 38.0681247947455,
    "word_count": 203
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Pexidartinib for Pain Relief in Tenosynovial Giant Cell Tumor"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomized 1:1 to receive pexidartinib (n=61) or placebo (n=59)"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults with symptomatic TGCT, randomized 1:1 to receive pexidartinib (n=61) or placebo (n=59) for 24 weeks."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized 1:1 to receive pexidartinib (n=61) or placebo (n=59) for 24 weeks."
      },
      "Objective": {
        "score": 1,
        "evidence": "evaluated the efficacy of pexidartinib in reducing pain in adults with tenosynovial giant cell tumor (TGCT) not amenable to surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was a â‰¥30% decrease in weekly mean worst-pain NRS score with <30% increase in narcotic use from baseline to week 25."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was via an integrated web response system, with allocation concealment."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "randomized 1:1 to receive pexidartinib (n=61) or placebo (n=59)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Pain response was observed in 31% (19/61) of the pexidartinib group versus 15% (9/59) of the placebo group"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Pain response was observed in 31% (19/61) of the pexidartinib group versus 15% (9/59) of the placebo group (p=0.03)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included liver toxicity."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02371369."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}